My little Bug,
I think this stock will be a big winner. Not only are the earnings doing well, but the AT111 trials seem to be going nicely also. I'm sure the FDA will make the company jump thru some hoops like with Carticel, which will likely provide more buying ops in the course of time. Expect both the CRO revenues and the transgenic collaborations to increase with time. Keep on milking those cows and goats and mice (but not the investors!) Moving right along with P3. Latest release:
Thursday July 24 10:13 AM EDT
Genzyme Transgenics sees Q4 start of trial
FRAMINGHAM, Mass., July 24 (Reuter) - Genzyme Transgenics said Thursday it expects to start it Phase III trial for recombinant human antithrombin III (ATIII) for blod clots in the fourth quarter.
Genzyme Transgenics said it has successfully completed preclinical safety studies with ATIII and a phase I clinical trial. A phase II trial was recently completed at Emory University in Atlanta, and the data are currently being analyzed.
The company expects to initiate a phase III trial in the fourth quarter of 1997.
The company Thursday reported a second-quarter net loss of $1.9 million, or $0.11 per share, compared to a net loss of $2.2 million in the second quarter of 1996, or $0.16 per share.
The loss resulted primarily from the company's continuing investment in transgenic research and development programs, including increased investment in clinical trials for ATIII, its lead product
Revenues from transgenic development collaborations were $4.2 million, an increase of 111 percent, compared to the second quarter of 1996. Contract research service revenues increased 22 percent to $11.4 million, compared to $9.4 million in the second quarter of 1996.
The increase was due to significant revenue growth from both contract research services and transgenic development collaborations. |
